Nivolumab-relatlimab safer than ipilimumab-nivolumab in advanced cutaneous melanoma
Treatment with nivolumab plus relatlimab results in a lower incidence of severe immune-related adverse events (irAEs), delayed onset of irAEs, and reduced rate of treatment discontinuation among patients with advanced cutaneous melanoma when compared with ipilimumab plus nivolumab, reports a study.
